Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
Want to see BLCO full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.15Last Year’s EPS
0.07Same Quarter Last Year
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized substantial progress on execution: consistent revenue growth, large adjusted EBITDA and margin expansion, strong Pharma and premium product momentum, active pipeline and elevated R&D investment — all supported by a modest guidance raise. Lowlights were mostly transitional or seasonal (Surgical field-force rebuild, weather-related disruptions, regional softness, prescription seasonality, and cash/capex timing). Overall, the positives—material margin improvement, strong product-level growth (notably Miebo, Xiidra, Daily SiHy, premium IOLs), and upgraded guidance—outweigh the temporary challenges.Company Guidance
Top-Line Growth
Total company revenue of $1.244 billion in Q1, up 6% year-over-year on a constant currency basis; FX provided a tailwind of approximately $42 million in the quarter.
Strong Adjusted EBITDA and Margin Expansion
Adjusted EBITDA of $200 million, up 59% year-over-year; adjusted EBITDA margin expanded to 16.1%, a 500 basis point improvement versus prior year.
Improved Gross and SG&A Margins Driving Operating Leverage
Adjusted gross margin of 61.2%, up 170 basis points year-over-year; adjusted SG&A margin improved by ~340 basis points, supporting meaningful operating leverage.
Pharmaceutical Segment Outperformance
Pharma revenue of $305 million, up 12% on a constant currency basis (14% reported); Miebo revenue of $76 million (+33% YoY) and Xiidra revenue of $87 million (+30% YoY) demonstrating strong prescription growth and commercialization execution.
Vision Care and Contact Lens Momentum
Vision Care revenue of $711 million, up 5% YoY; contact lens revenue +5% with Daily SiHy growth of ~23% (management cited 23–25% range) and Ultra up 3%; U.S. contact lens growth +6%, international +4%.
Premium Surgical Franchise Progress
Surgical premium IOLs grew 27% constant currency; enVista U.S. sales +16% and Envy product up 88% YoY; U.S. system placements were nearly 3x prior-year levels, indicating strong premium adoption.
Pipeline and Regulatory Milestones
NDA filed for LUMIFY NXT and CE Mark submission completed for seeLYRA; PreserVision AREDS3 and Blink Triple Care preservative-free shipped in Q1; management highlighted active pipeline with 60+ programs advancing.
Increased R&D Investment While Growing Profitability
Invested approximately $101 million in adjusted R&D in Q1, an increase of ~15–17% YoY, while delivering substantial margin expansion—indicative of growth plus innovation balance.
Raised 2026 Financial Guidance
Full-year revenue guidance increased by $45 million to $5.42B–$5.52B (constant currency growth ~5.3%–7.2%); full-year adjusted EBITDA guidance raised by $10 million to $1.01B–$1.06B (implied margin ~19% at midpoint).
Improved Cash/Capital and Leverage Progress
Adjusted EPS (ex Acquired IPR&D) of $0.08 vs. loss of $0.07 prior year; net leverage improved in the quarter with a target to reach ~3.5x by end of 2028; Q1 CapEx $100 million (full-year ~ $285 million) and adjusted operating cash flow of $45 million reflecting seasonal cadence.
BLCO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BLCO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $15.72 | $15.34 | -2.42% |
Feb 18, 2026 | $17.73 | $17.67 | -0.34% |
Oct 29, 2025 | $15.20 | $15.47 | +1.78% |
Jul 30, 2025 | $14.65 | $13.71 | -6.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bausch + Lomb Corporation (BLCO) report earnings?
Bausch + Lomb Corporation (BLCO) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Bausch + Lomb Corporation (BLCO) earnings time?
Bausch + Lomb Corporation (BLCO) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLCO EPS forecast?
BLCO EPS forecast for the fiscal quarter 2026 (Q2) is 0.15.
